Dark

Check out our Dark Pool Levels

ATRS
Antares Pharma, Inc.
stock NASDAQ

Inactive

May 23, 2022

5.59USD0.000%(0.00)2,707,496

Pre-market

0.00USD-100.000%(-5.59)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 18, 2022

07:31AM EST Antares Pharma Receives FDA Fast Track Designation For ATRS-1902 For Adrenal Crisis Rescue Benzinga

07:30AM EST Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 GlobeNewswire Inc

Jan 12, 2022

08:30AM EST Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, announced today the appointment of Claude E. Richardson as Senior Vice President of Human Resources. Mr. Richardson will be responsible for Antares corporate Human Resources (HR) strategy and development. GlobeNewswire Inc

Jan 11, 2022

07:36AM EST Antares Pharma Announces Positive Results From Phase I Study Of ATRS-1902 For Adrenal Crisis Rescue RTTNews

07:34AM EST Antares Pharma Announces Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue; Co. Reports 'The results of the Phase I cross-over study met its primary objective showing ATRS-1902 delivered a comparable pharmacokinetic profile to Solu-Cortef' Benzinga

07:33AM EST Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue Benzinga

07:30AM EST Antares Pharma Announces Positive Results From Phase I Study For GlobeNewswire Inc

Dec 20, 2021

09:47AM EST 5 Value Stocks In The Healthcare Sector Benzinga

Dec 16, 2021

08:20AM EST The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street Benzinga

Dec 15, 2021

05:58PM EST Antares Pharma Announces Divestiture of Otrexup GlobeNewswire Inc

Dec 7, 2021

07:21AM EST Antares Pharma Granted U.S. Patent #11,191,908 'Syringe shock absorber for use in an injection device' Benzinga

Nov 30, 2021

04:52PM EST Antares Pharma Granted U.S. Patent #11,185,642 'Injection device with cammed ram assembly' Benzinga

Nov 22, 2021

08:00AM EST Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29-December 2, 2021. GlobeNewswire Inc

Nov 15, 2021

11:21AM EST Overview Of Value Stocks In The Healthcare Sector Benzinga

Nov 10, 2021

08:30AM EST Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Jefferies London Healthcare Conference being held November 16-19, 2021. GlobeNewswire Inc

Nov 5, 2021

09:37AM EDT HC Wainwright & Co. Maintains Buy on Antares Pharma, Lowers Price Target to $5 Benzinga

Nov 4, 2021

07:40AM EDT Antares Pharma Q3 EPS $0.03, Inline, Sales $48.19M Miss $48.33M Estimate Benzinga

07:00AM EDT Antares Pharma Reports Third Quarter 2021 Financial and Operating GlobeNewswire Inc

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Oct 28, 2021

08:00AM EDT Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced the appointment of Carmen Volkart to its Board of Directors. Ms. Volkart will also serve as a Member of the Audit Committee. Ms. Volkart is a seasoned medical device executive with extensive finance and operations experience at publicly traded and private companies. GlobeNewswire Inc

Oct 25, 2021

11:20AM EDT Overview Of Value Stocks In The Healthcare Sector Benzinga

08:30AM EDT Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that an abstract on XYOSTED, a subcutaneous testosterone enanthate injection, was accepted as on oral presentation at the 22nd Annual Fall Scientific Meeting of SMSNA in Scottsdale, AZ on October 21-24, 2021. GlobeNewswire Inc

Oct 21, 2021

08:30AM EDT Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced it will release its third quarter 2021 financial and operating results on Thursday, November 4, 2021, before the market opens. GlobeNewswire Inc

Oct 18, 2021

12:56PM EDT Lipocine, Antares Ink Licensing Pact For Testosterone Replacement Therapy In US Benzinga

07:12AM EDT Antares Pharma Enters Into Exclusive License Agreement With Lipocine For TLANDO In U.S.; Lipocine Received An Upfront Payment Of $11M And Is Eligible For Additional Milestone Payments Up To $10M And Tiered Royalty And Commercial Milestones Benzinga

07:00AM EDT Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that it entered into an exclusive license agreement with Lipocine Inc. (Lipocine), a clinical-stage biopharmaceutical company, for TLANDO (testosterone undecanoate), an oral treatment for testosterone replacement therapy (TRT) in the United States (U.S.). GlobeNewswire Inc

Sep 30, 2021

09:02AM EDT Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue Benzinga

09:00AM EDT Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal GlobeNewswire Inc

Sep 27, 2021

10:20AM EDT 5 Value Stocks To Watch In The Healthcare Sector Benzinga

Sep 8, 2021

08:30AM EDT Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, will participate and host investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference being held on September 13-15, 2021. GlobeNewswire Inc

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

07:28AM EDT Antares Pharma Reaffirms FY21 Sales Guidance Benzinga

07:28AM EDT Antares Pharma Q2 EPS $0.03 Beats $0.01 Estimate, Sales $44.98M Beat $42.98M Estimate Benzinga

07:00AM EDT Antares Pharma Reports Second Quarter 2021 Financial and Operating GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 28, 2021

08:30AM EDT Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced it will release its second quarter 2021 financial and operating results on Thursday, August 5, 2021, before the market opens. GlobeNewswire Inc

Jul 22, 2021

09:59AM EDT Antares To Start Testing ATRS-1902 With Injector Technology In Patients With Adrenal Crisis Benzinga

08:36AM EDT Antares Pharma Announces FDA Acceptance Of IND Application For ATRS-1902 For Adrenal Crisis Rescue Benzinga

08:30AM EDT Antares Pharma Announces FDA Acceptance of IND Application for GlobeNewswire Inc

Jul 16, 2021

10:15AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 16, 2021 Benzinga

06:44AM EDT Truist Securities Initiates Coverage On Antares Pharma with Buy Rating, Announces Price Target of $7 Benzinga

Jul 7, 2021

08:30AM EDT Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Ladenburg Thalmann Annual Healthcare Conference. GlobeNewswire Inc

Jun 28, 2021

08:39AM EDT Antares Pharma Announces Partner Idorsia Initiates Phase 3 Study With Selatogrel For Acute Myocardial Infarction RTTNews

08:30AM EDT Antares Pharma Announces Partner Idorsia Initiates the Phase 3 GlobeNewswire Inc

05:38AM EDT Idorsia Initiates the Phase 3 Registration Study With Selatogrel Using Antares' Autoinjector for the Treatment of Acute Myocardial Infarction Benzinga

Jun 22, 2021

09:01AM EDT Antares Pharma Reports Submission Of Investigational New Drug Application For ATRS-1902 For Adrenal Crisis Rescue Benzinga

09:00AM EDT Antares Pharma Announces Submission of IND Application for GlobeNewswire Inc

Jun 15, 2021

08:30AM EDT Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Raymond James Human Health Innovations Conference. GlobeNewswire Inc

May 26, 2021

08:30AM EDT Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Jefferies Virtual Healthcare Conference. GlobeNewswire Inc

May 10, 2021

09:20AM EDT Antares Pharma Posts Clinical Trial Titled 'Phase 1 Study of ATRS-2002 in Healthy Male Adults' To ClinicalTrials.Gov Benzinga

06:32AM EDT HC Wainwright & Co. Maintains Buy on Antares Pharma, Raises Price Target to $5 Benzinga

May 6, 2021

10:04AM EDT Antares Pharma shares were trading higher after the company reported better-than-expected Q1 EPS and sales results. Benzinga

08:12AM EDT Antares Pharma Reaffirms FY21 Sales Guidance Of $175M-$200M Benzinga

08:11AM EDT Antares Pharma Q1 EPS $0.02 Beats $0.01 Estimate, Sales $42.08M Beat $38.47M Estimate Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

07:15AM EDT Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests. GlobeNewswire Inc

07:00AM EDT Antares Pharma Reports First Quarter 2021 Financial and Operating GlobeNewswire Inc

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

May 3, 2021

08:30AM EDT Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that data highlighting the therapeutic potential of subcutaneous testosterone enanthate in younger hypogonadal populations was presented in a poster presentation at the Pediatric Endocrine Society (PES) 2021 Virtual Annual Meeting on April 30 May 3, 2021. GlobeNewswire Inc

Apr 28, 2021

08:30AM EDT Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to participate and host investor meetings at the 7th Annual Truist Securities 2021 Life Sciences Summit being held virtually on May 4-5, 2021. GlobeNewswire Inc

Apr 27, 2021

08:30AM EDT Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced it will release its first quarter 2021 financial and operating results on Thursday, May 6, 2021, before the market opens. GlobeNewswire Inc

Apr 26, 2021

08:30AM EDT Antares Pharma Appoints Dr. Peter Richardson as Executive Vice GlobeNewswire Inc

Apr 22, 2021

11:37AM EDT Antares Pharma US Patent & Trademark Office Abstract 'Needle Assisted Injection Device Having Reduced Trigger Force' Benzinga

Mar 2, 2021

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

07:25AM EST Antares Pharma Reaffirms FY21 Sales Guidance of $175M-$200M Benzinga

07:22AM EST Antares Pharma Q4 EPS $0.03, Inline, Sales $44.13M Beat $40.75M Estimate Benzinga

07:22AM EST Recap: Antares Pharma Q4 Earnings Benzinga

07:00AM EST Antares Pharma Reports Fourth Quarter and Full-Year 2020 Financial GlobeNewswire Inc

03:40AM EST Earnings Scheduled For March 2, 2021 Benzinga

Mar 1, 2021

10:14AM EST Antares Pharma's Earnings: A Preview Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 24, 2021

04:30PM EST Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present and host investor meetings at the Raymond James 42nd Annual Virtual Institutional Investors Conference and the Cowen 41st Annual Virtual Healthcare Conference. GlobeNewswire Inc

Feb 23, 2021

08:30AM EST Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a pharmaceutical technology company, today announced it will release its fourth quarter and full-year 2020 financial and operating results on Tuesday, March 2, 2021, before the market opens. GlobeNewswire Inc

Feb 19, 2021

07:25AM EST The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko Benzinga

Feb 17, 2021

08:30AM EST Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to participate and host investor meetings at the SVB Leerink 10th Annual Virtual Global Healthcare Conference being held on February 22-26, 2021. GlobeNewswire Inc

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Jan 26, 2021

08:07AM EST The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market Benzinga

Jan 11, 2021

08:03AM EST Antares Pharma Narrows FY20 Sales Guidance From $135M-$155M To $145M-$150M Vs. $145.6M Est.; Sees FY21 Sales $175M-$200M Vs. $187.24M Est Benzinga

08:00AM EST Antares Pharma Announces Full-Year 2021 Revenue Guidance of GlobeNewswire Inc

Nov 23, 2020

04:05PM EST Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer has participated in a fireside chat presentation and will host investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held on December 1-3, 2020. GlobeNewswire Inc

Nov 5, 2020

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

07:20AM EST Antares Pharma Reaffirms FY20 Sales Guidance Benzinga

07:19AM EST Antares Pharma Q3 EPS $0.03 Beats $0.02 Estimate, Sales $40.00M Beat $35.67M Estimate Benzinga

07:00AM EST Antares Pharma Reports Strong Third Quarter 2020 Financial and GlobeNewswire Inc

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

08:59AM EST Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 22, 2020

08:30AM EDT Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a pharmaceutical technology company, today announced it will release its third quarter 2020 financial and operating results on Thursday, November 5, 2020, before the market opens. GlobeNewswire Inc

Oct 1, 2020

09:04AM EDT Antares Pharma Reports Exclusive License Deal With Ferring Pharma For Nocdurna In US Benzinga

08:47AM EDT Antares Pharma Enters Exclusive License Agreement With Ferring GlobeNewswire Inc

Sep 8, 2020

08:01AM EDT Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference. GlobeNewswire Inc

Aug 10, 2020

07:00AM EDT Antares Pharma Appoints Tram Bui as Vice President of Corporate GlobeNewswire Inc

Aug 6, 2020

10:45AM EDT Antares Pharma Earlier Reported Q2 EPS $0.01 Up From $(0.01) YoY, Sales $32.38M Beat $30.38M Estimate Benzinga

07:01AM EDT -- Second Quarter 2020 Revenue of $32.4 Million, a 14% Increase Compared to Second Quarter 2019 -- Second Quarter 2020 Net Income of $2.2 Million as Compared to Net Loss of $2.2 Million for Second Quarter 2019 -- Reinstates Full-Year 2020 Revenue Guidance Range of $135 to $155 Million GlobeNewswire Inc

Aug 3, 2020

03:52PM EDT Why Antares Pharma's Stock Is Trading Higher Today Benzinga

07:11AM EDT Antares Pharma Announces Deal with Lunatus Global to Distribute and Promote XYOSTED in Saudi Arabia Benzinga

07:00AM EDT Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced they have entered into an exclusive distribution agreement with Lunatus Global Medical Supplies (Lunatus) to distribute and promote the sale of XYOSTED in Saudi Arabia and the United Arab Emirates (UAE). GlobeNewswire Inc

Jul 30, 2020

07:00AM EDT Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced it will release its second quarter 2020 financial results and recent operating progress before the market opens on Thursday, August 6, 2020. Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on August 6, 2020 to discuss the results. GlobeNewswire Inc

Jul 21, 2020

07:11AM EDT First Commercial Product Using Antares Pharma's Multi-Dose Pen Platform Launches in Europe Benzinga

07:00AM EDT First Commercial Product Using Antares Pharmas GlobeNewswire Inc

Jul 20, 2020

07:00AM EDT Antares Pharma Appoints Patrick Shea Senior Vice President of GlobeNewswire Inc

Share